Skip to main content

Breadcrumb

  1. Home

Health Plan

Valid for Measure Submission

Medication Management for People with Asthma

  • The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported.
    1. The percentage of patients who remained on an asthma controller medication for at least 50% of their treatment period.
    2. The percentage of patients who remained on an asthma controller medication for at least 75% of their treatment period.

    CBE ID
    1799

Medication Reconciliation Post-Discharge

  • The percentage of discharges from January 1–December 1 of the measurement year for patients 18 years of age and older for whom medications were reconciled the date of discharge through 30 days after discharge (31 days total).

    CBE ID
    0097

Medication Reconciliation Post-Discharge (MRP)

  • The percentage of discharges during the first 11 months of the measurement year (e.g., January 1–December 1) for patients 66 years of age and older for whom medications were reconciled on or within 30 days of discharge.

    CBE ID
    0554

Methotrexate: CBC within 12 weeks

  • This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim

    CBE ID
    0598

Methotrexate: Creatinine within 12 weeks

  • This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim.

    CBE ID
    0599

Methotrexate: LFT within 12 weeks

  • This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a liver function test (LFT) in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.

    CBE ID
    0597

MI - Use of Beta Blocker Therapy

  • The percentage of patients aged 18 years and older diagnosed with myocardial infarction (MI) who are taking a beta blocker

    CBE ID
    0613e

Minimizing Institutional Length of Stay

  • The proportion of admissions to an institutional facility (e.g., nursing facility, intermediate care facility for individuals with intellectual disabilities [ICF/IID]) for managed long-term services and support (MLTSS) plan enrollees that result in successful discharge to the community (community residence for 60 or more days) within 100 days of admission. This measure is reported as an observed rate and a risk-adjusted rate.

    CBE ID
    3457

NCQA Supplemental items for CAHPS® 4.0 Adult Questionnaire (CAHPS 4.0H)

  • This supplemental set of items was developed jointly by NCQA and the AHRQ-sponsored CAHPS Consortium and is intended for use with the CAHPS 4.0 Health Plan survey. Some items are intended for Commercial health plan members only and are not included here. This measure provides information on the experiences of Medicaid health plan members with the organization. Results summarize member experiences through composites and question summary rates.

    CBE ID
    0007